Dragonfly Therapeutics Announces Celgene In-license of First Two TriNKET Immunotherapy Drug…
Dragonfly Therapeutics announced it has licensed two TriNKET immunotherapy drug candidates to Celgene Corporation and its affiliates for $12m each plus prospective milestones and…
Read More...
Read More...
